HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS CONFERENCE CALENDAR
LATEST UPDATES » Vol 22, No 02, February 2018 – Searching for the fountain of youth       » Chinese researchers cloned monkeys       » National Science and Technology Prizes       » Highlights from the State Natural Science Award       » Highlights from the State Technological Invention Award      
BIOBOARD - SINGAPORE & TAIWAN
ASIT biotech announces follow-up study of Phase I/IIa clinical trial for house dust mite rhinitis
A subset of patients treated during the Phase I/IIa clinical trial with its hdm-ASIT+™ product candidate for house dust mite rhinitis will undergo a complementary medical visit to assess potential long-term effect of hdm-ASIT+™.


ASIT biotech, a Belgian clinical-stage biopharmaceutical company focused on the research, development and future commercialization of breakthrough immunotherapy products for the treatment of allergies, announces it has received the approval of the regulatory authorities and ethical committee to start a follow-up study with the patients enrolled during the Phase I/IIa clinical trial of its product candidate for house dust mite rhinitis.

The study is carried out at the Carl Gustav Carus University Hospital in Dresden, Germany. The conjunctival provocation test (CPT) showed a slight numerical difference in favor of the treated group compared to the placebo group in the original study. The objective of this follow-up study is to evaluate whether longer natural exposure to house dust mites may have an impact on immunological and reactivity parameters, and assess a potential long-term effect of hdm-ASIT+™.

A subset of the 36 initially randomized patients (27 treated with hdm-ASIT+™ and 9 with placebo) will undergo a complementary medical visit in order to assess their reactivity score to a CPT and their titles of house dust mite allergen specific antibodies (IgG, IgG4, IgE and blocking antibodies).

Thierry Legon, CEO of ASIT biotech, says, “The immunogenicity parameters and CPT score that were tested as a secondary endpoint one week after the end of the treatment with hdm-ASIT+™ were improved between the treated group and the placebo. It is clinically and scientifically sound to test a potential long-term effect of our product against house dust mite-induced rhinoconjunctivitis. An increase of the IgG4 and the blocking antibodies associated to a reduction of the CPT score in treated patients would show that a long term natural challenge is needed to allow the treatment clinical efficacy. In parallel to this follow-up study, we are actively working on the design of an optimized version of hdm-ASIT+™ based on our improved understanding of the mechanism of action of our lead product gp-ASIT+™ following the results of the Phase III study in grass pollen rhinitis.”

Source: ASIT biotech

Click here for the complete issue.

NEWS CRUNCH  
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
news Separation of conjoined twins presents surgical and ethical challenges for MassGeneral Hospital for Children staff
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  

Lady Ganga: Nilza'S Story
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Nutrition / Women in Science
April:
Digestive health / Intellectual property
May:
Asthma / Dental health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy